Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis

被引:0
|
作者
Pohl, Sarah B. [1 ]
Engelbertz, Christiane [1 ]
Reinecke, Holger [1 ]
Malyar, Nasser M. [1 ]
Meyborg, Matthias [1 ]
Brix, Tobias J. [2 ]
Varghese, Julian [2 ]
Gebauer, Katrin [1 ,3 ]
机构
[1] Univ Hosp Muenster, Dept Cardiol Coronary & Peripheral Vasc Dis 1, Heart Failure, Cardiol, D-48149 Munster, Germany
[2] Univ Munster, Inst Med Informat, D-48149 Munster, Germany
[3] Univ Hosp Muenster, Dept Cardiol Coronary & Peripheral Vasc Dis 1, Heart Failure, Albert Schweitzer Campus 1,Geb A1, D-48149 Munster, Germany
关键词
Cholesterol; Statin; Hyperchole-; sterolemia; Lipid-lowering therapy; Secondary prevention; Ezetimibe; CORONARY-HEART-DISEASE; STATIN; METAANALYSIS; MANAGEMENT; EFFICACY; PLACEBO; TRIAL;
D O I
10.1016/j.numecd.2024.03.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Atherosclerotic cardiovascular disease (ASCVD) is the most common cause of death in Europe. Although the 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the management of dyslipidaemias claim a target low-density lipoprote in cholesterol (LDL-C) value of <55 mg/dL for very high-risk patients by use of lipidlowering therapy (LLT) and lifestyle adaptations, the target level achievement is not satisfactory. We examined LLT use in ASCVD patients exceeding LDL-C target levels at admission and its adaptations at discharge. Methods and results: Between January 2017 and February 2020, 1091 patients with LDL-C >100 mg/dL and ASCVD defined as diagnosis of angina pectoris (AP, n = 179), acute myocardial infarction (AMI, n = 317), chronic ischemic heart disease (CHD, n = 195), or peripheral artery disease (PAD, n = 400) were extracted from hospital records. LLT use on admission and discharge as well as recommendations on lifestyle and nutrition were analysed. On admission, 51% of the patients were not taking LLT. At discharge, 91% were prescribed statins and 87% were advised on lifestyle adaptation and/or pharmacological treatment. Highintensity statin use at discharge was present in 63% of the AP-group, 92% of the AMI-group, 62% of the CHD-group and 71% of the PAD-group. Ezetimibe was present in 16% and proprotein convertase subtilisin/kexin 9 inhibitors (PCSK9i) in 1%. However, of those on high-intensity statin, 25% remained on insufficient statin dosage. Conclusion: Switch to high-intensity statins and use of ezetimibe and PCSK9i was low in chronic ASCVD patients. Even though statin intake was high in high-risk patients, target levels were still not reached. (c) 2024 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1670 / 1680
页数:11
相关论文
共 50 条
  • [1] Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
    Bi, Lei
    Yi, Jiayi
    Wu, Chaoqun
    Hu, Shuang
    Zhang, Xingyi
    Lu, Jiapeng
    Liu, Jiamin
    Zhang, Haibo
    Yang, Yang
    Cui, Jianlan
    Xu, Wei
    Song, Lijuan
    Guo, Yuanlin
    Li, Xi
    Zheng, Xin
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [2] Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry
    De Luca, Leonardo
    Arca, Marcello
    Temporelli, Pier Luigi
    Meessen, Jennifer
    Riccio, Carmine
    Bonomo, Paolo
    Colavita, Angela Rita
    Gabrielli, Domenico
    Gulizia, Michele Massimo
    Colivicchi, Furio
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 316 : 229 - 235
  • [3] Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease
    Nanna, Michael G.
    Nelson, Adam J.
    Haynes, Kevin
    Shambhu, Sonali
    Eapen, Zubin
    Cziraky, Mark J.
    Calvert, Sara B.
    Pagidipati, Neha J.
    Granger, Christopher B.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 (04) : 1243 - 1249
  • [4] Lipid-lowering therapy today: Treating the high-risk cardiovascular patient
    Berra, Kathleen
    JOURNAL OF CARDIOVASCULAR NURSING, 2008, 23 (05) : 414 - 421
  • [5] Lipid-Lowering Treatment and the Lipid Goals Attainment in Patients with a Very High Cardiovascular Risk
    Lis, Anna
    Lis, Paulina
    Lowicka, Weronika
    Grabarczyk, Malgorzata
    Wita, Michal
    Zarczynski, Piotr
    Zarczynska, Malgorzata
    Haberka, Maciej
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (08)
  • [6] A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients
    Sabouret, Pierre
    Angoulvant, Denis
    Pathak, Atul
    Costa, Francesco
    Pezel, Theo
    Michos, Erin D.
    CURRENT CARDIOVASCULAR RISK REPORTS, 2019, 13 (11)
  • [7] Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?
    Roever, Leonardo
    Biondi-Zoccai, Giuseppe
    Rao, Sunil V.
    CLINICAL THERAPEUTICS, 2017, 39 (03) : 659 - 660
  • [8] Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
    Cannon, Christopher P.
    Khan, Irfan
    Klimchak, Alexa C.
    Reynolds, Matthew R.
    Sanchez, Robert J.
    Sasiela, William J.
    JAMA CARDIOLOGY, 2017, 2 (09) : 959 - 966
  • [9] STEP-RCV Project: ScienTific Expert Panel for patients at high and very high cardiovascular risk: how to optimize lipid-lowering therapy
    Colivicchi, Furio
    Arca, Marcello
    Di Fusco, Stefania Angela
    Pirillo, Angela
    Catapano, Alberico L.
    GIORNALE ITALIANO DI CARDIOLOGIA, 2024, 25 (05) : 318 - 326
  • [10] Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial
    Lee, Jung-Hee
    Ahn, Sung Gyun
    Jeon, Ho Sung
    Lee, Jun-Won
    Youn, Young Jin
    Lee, Yong-Joon
    Lee, Seung-Jun
    Hong, Sung-Jin
    Ahn, Chul-Min
    Ko, Young-Guk
    Kim, Jung-Sun
    Choi, Donghoon
    Hong, Myeong-Ki
    Jang, Yangsoo
    Kim, Byeong-Keuk
    JOURNAL OF CLINICAL LIPIDOLOGY, 2024, 18 (06) : e905 - e914